1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Anti-Infective Agents Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Anti-Infective Agents Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Rising Prevalence of Targeted Diseases
5.2 Market Opportunities
- 5.2.1 Rising Government Support for Research Activities
5.3 Future Trends
- 5.3.1 Development of New Anti-infective Agents
5.4 Impact of Drivers and Restraints
6. Europe Anti-Infective Agents Market Regional Analysis
6.1 Europe Anti-Infective Agents Market Overview
6.2 Europe Anti-Infective Agents Market Revenue 2020-2028 (US$ Million)
6.3 Europe Anti-Infective Agents Market Forecast Analysis
7. Europe Anti-Infective Agents Market Analysis – by Type
7.1 Anti-Viral
- 7.1.1 Overview
- 7.1.2 Anti-Viral: Europe Anti-Infective Agents Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Anti-Bacterial
- 7.2.1 Overview
- 7.2.2 Anti-Bacterial: Europe Anti-Infective Agents Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Anti-Fungal
- 7.3.1 Overview
- 7.3.2 Anti-Fungal: Europe Anti-Infective Agents Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Anti-Infective Agents Market Analysis – by Range
8.1 Narrow Spectrum and Broad Spectrum
- 8.1.1 Overview
- 8.1.2 Narrow Spectrum and Broad Spectrum: Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Anti-Infective Agents Market Analysis – by Route of Administration
9.1 IV
- 9.1.1 Overview
- 9.1.2 Narrow Spectrum and Broad Spectrum: Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Oral
- 9.2.1 Overview
- 9.2.2 Narrow Spectrum and Broad Spectrum: Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Topical
- 9.3.1 Overview
- 9.3.2 Narrow Spectrum and Broad Spectrum: Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
10. Europe Anti-Infective Agents Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Anti-Infective Agents Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 10.1.1.1 Europe Anti-Infective Agents Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.1 UK: Europe Anti-Infective Agents Market Breakdown, by Type
- 10.1.1.1.2 UK: Europe Anti-Infective Agents Market Breakdown, by Range
- 10.1.1.1.3 UK: Europe Anti-Infective Agents Market Breakdown, by Route of Administration
- 10.1.1.2 Germany:
Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.1 Germany: Europe Anti-Infective Agents Market Breakdown, by Type
- 10.1.1.2.2 Germany: Europe Anti-Infective Agents Market Breakdown, by Range
- 10.1.1.2.3 Germany: Europe Anti-Infective Agents Market Breakdown, by Route of Administration
- 10.1.1.3 France:
Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.1 France: Europe Anti-Infective Agents Market Breakdown, by Type
- 10.1.1.3.2 France: Europe Anti-Infective Agents Market Breakdown, by Range
- 10.1.1.3.3 France: Europe Anti-Infective Agents Market Breakdown, by Route of Administration
- 10.1.1.4 Russia:
Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.4.1 Russia: Europe Anti-Infective Agents Market Breakdown, by Type
- 10.1.1.4.2 Russia: Europe Anti-Infective Agents Market Breakdown, by Range
- 10.1.1.4.3 Russia: Europe Anti-Infective Agents Market Breakdown, by Route of Administration
- 10.1.1.5 Italy:
Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.5.1 Italy: Europe Anti-Infective Agents Market Breakdown, by Type
- 10.1.1.5.2 Italy: Europe Anti-Infective Agents Market Breakdown, by Range
- 10.1.1.5.3 Italy: Europe Anti-Infective Agents Market Breakdown, by Route of Administration
- 10.1.1.6 Rest of Europe:
Europe Anti-Infective Agents Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Anti-Infective Agents Market Breakdown, by Type
- 10.1.1.6.2 Rest of Europe: Europe Anti-Infective Agents Market Breakdown, by Range
- 10.1.1.6.3 Rest of Europe: Europe Anti-Infective Agents Market Breakdown, by Route of Administration
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Anti-Infective Agents Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Abbott
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Allergan Plc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Astellas Pharma Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bayer AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Boehringer Ingelheim International GmbH
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Bristol-Myers Squibb Company
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 F. Hoffmann-La Roche Ltd.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Gilead Sciences, Inc.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 GlaxoSmithKline plc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Merck & Co., Inc.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Novartis AG
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
14. Appendix
14.1 About Business Market Insights